Catalyst Pharmaceuticals Inc. (Nasdaq: CPRX) reported positive results from the investigator-sponsored trial of Firdapse to treat myasthenia gravis patients with anit-MuSK antibodies. Shares of the biopharmaceutical climbed 38 cents to close at $1.55.
Catalyst Pharmaceuticals reports positive results
March 15, 2017 at 18:27 PM EDT
